MOLECULAR INFORMATION
Molecular information
- Type
- D-retro-inverso peptide · disrupts FOXO4-p53 interaction · senolytic
FOX04-DRI is a senolytic peptide originating from a single research paper, sold grey-market for longevity claims.
Claims vs evidence
- Senolytic clearance of senescent cells — Baar et al. 2017 mouse data
- Tissue rejuvenation / lifespan extension — extrapolated from rodent results, no human trial
- Hair regrowth, skin youthfulness — vendor claims, no data
Why we grade it D
Single-source seminal paper without independent replication or human translation. The senolytic mechanism class is genuine emerging science, but specific compounds in that class require clinical-trial evidence to support marketed use.
Frequently asked questions
- What is FOX04-DRI?
- A D-retro-inverso peptide designed by the Erasmus / de Keizer lab to disrupt the FOXO4-p53 interaction in senescent cells. Demonstrated senolytic activity in mice; sold grey-market under "FOX04" or "FOXO4-DRI" naming for longevity claims.
- Is FOX04-DRI authorised?
- No — preclinical research compound only. No human trials are registered with major regulators; the senolytic field as a whole is still in early clinical translation.
- Why grade D?
- The Baar et al. 2017 Cell paper is the foundational source; replication in independent labs is sparse, human safety data is absent, and dosing for clinical effect is unknown. Grey-market vendors sell it with claims that aren't supported by trials.